Allogene Therapeutics ALLO Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's business segments — net loss?
- Allogene Therapeutics (ALLO) reported business segments — net loss of -$42.61M in Q1 2026.
- How has Allogene Therapeutics's business segments — net loss changed year-over-year?
- Allogene Therapeutics's business segments — net loss increased by 28.7% year-over-year, from -$59.73M to -$42.61M.
- What is the long-term trend for Allogene Therapeutics's business segments — net loss?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — net loss has grown at a -23.6% compound annual growth rate (CAGR), from -$327.27M to -$190.89M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the segment after accounting for all revenues and operating expenses. For clinical-stage biotech companies, this typically reflects the net cash burn required to fund ongoing research and development. It is the primary measure of the segment's current financial sustainability.